Topotecan in the treatment of gynecologic cancer

R. L. Coleman, D. S. Miller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a derivative of the topoisomerase I inhibitor camptothecin, was approved by the Food and Drug Administration in May 1996 for the salvage treatment of ovarian cancer. It has shown promising clinical activity in a variety of solid tumors, including cervical cancer. Phase II and III trials in patients with cisplatin-resistant ovarian cancer have been conducted using a regimen of a single 30-minute intravenous topotecan infusion (1.5 mg/m2/d) for 5 days, repeated every 21 days. Significant responses, both partial and complete, have been observed in 14% to 21% of patients, with stable disease achieved in as many as 61%. In advanced or recurrent cervical cancer, partial response or stable disease was achieved in 59% of phase II trial patients. Myelosuppression is the major dose-limiting toxicity associated with topotecan. In general, the severity of myelosuppression shows a positive correlation to the magnitude of exposure to topotecan. Support with granulocyte colony-stimulating factor may partially ameliorate myelosuppressive effects.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number6 SUPPL. 20
StatePublished - 1997

Fingerprint

Topotecan
Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Topoisomerase I Inhibitors
Therapeutics
Salvage Therapy
Camptothecin
Granulocyte Colony-Stimulating Factor
United States Food and Drug Administration
Intravenous Infusions
Cisplatin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Topotecan in the treatment of gynecologic cancer. / Coleman, R. L.; Miller, D. S.

In: Seminars in Oncology, Vol. 24, No. 6 SUPPL. 20, 1997.

Research output: Contribution to journalArticle

Coleman, R. L. ; Miller, D. S. / Topotecan in the treatment of gynecologic cancer. In: Seminars in Oncology. 1997 ; Vol. 24, No. 6 SUPPL. 20.
@article{acdf59dee7ba451786623c85d250a275,
title = "Topotecan in the treatment of gynecologic cancer",
abstract = "Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a derivative of the topoisomerase I inhibitor camptothecin, was approved by the Food and Drug Administration in May 1996 for the salvage treatment of ovarian cancer. It has shown promising clinical activity in a variety of solid tumors, including cervical cancer. Phase II and III trials in patients with cisplatin-resistant ovarian cancer have been conducted using a regimen of a single 30-minute intravenous topotecan infusion (1.5 mg/m2/d) for 5 days, repeated every 21 days. Significant responses, both partial and complete, have been observed in 14{\%} to 21{\%} of patients, with stable disease achieved in as many as 61{\%}. In advanced or recurrent cervical cancer, partial response or stable disease was achieved in 59{\%} of phase II trial patients. Myelosuppression is the major dose-limiting toxicity associated with topotecan. In general, the severity of myelosuppression shows a positive correlation to the magnitude of exposure to topotecan. Support with granulocyte colony-stimulating factor may partially ameliorate myelosuppressive effects.",
author = "Coleman, {R. L.} and Miller, {D. S.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 20",

}

TY - JOUR

T1 - Topotecan in the treatment of gynecologic cancer

AU - Coleman, R. L.

AU - Miller, D. S.

PY - 1997

Y1 - 1997

N2 - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a derivative of the topoisomerase I inhibitor camptothecin, was approved by the Food and Drug Administration in May 1996 for the salvage treatment of ovarian cancer. It has shown promising clinical activity in a variety of solid tumors, including cervical cancer. Phase II and III trials in patients with cisplatin-resistant ovarian cancer have been conducted using a regimen of a single 30-minute intravenous topotecan infusion (1.5 mg/m2/d) for 5 days, repeated every 21 days. Significant responses, both partial and complete, have been observed in 14% to 21% of patients, with stable disease achieved in as many as 61%. In advanced or recurrent cervical cancer, partial response or stable disease was achieved in 59% of phase II trial patients. Myelosuppression is the major dose-limiting toxicity associated with topotecan. In general, the severity of myelosuppression shows a positive correlation to the magnitude of exposure to topotecan. Support with granulocyte colony-stimulating factor may partially ameliorate myelosuppressive effects.

AB - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a derivative of the topoisomerase I inhibitor camptothecin, was approved by the Food and Drug Administration in May 1996 for the salvage treatment of ovarian cancer. It has shown promising clinical activity in a variety of solid tumors, including cervical cancer. Phase II and III trials in patients with cisplatin-resistant ovarian cancer have been conducted using a regimen of a single 30-minute intravenous topotecan infusion (1.5 mg/m2/d) for 5 days, repeated every 21 days. Significant responses, both partial and complete, have been observed in 14% to 21% of patients, with stable disease achieved in as many as 61%. In advanced or recurrent cervical cancer, partial response or stable disease was achieved in 59% of phase II trial patients. Myelosuppression is the major dose-limiting toxicity associated with topotecan. In general, the severity of myelosuppression shows a positive correlation to the magnitude of exposure to topotecan. Support with granulocyte colony-stimulating factor may partially ameliorate myelosuppressive effects.

UR - http://www.scopus.com/inward/record.url?scp=0031474058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031474058&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 20

ER -